1[1]Rousseau FS,Wakeford C,Mommeja-marin H,et al.Pro-spective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency vi-res-infected patients[J].J InfectDis,2003,188(11):1652～1658.
2[2]Wang LH,Begiey J,St Claire RL,et al.Pharmacokinetic and Pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV in fection[J].AIDS Res Hun Retroviruses,2004,20(11):1173.
3[3]Younger HM,Bathgate AI,Hayes PC.Review article:nucleoside analogues for the treatment of chronic hepatitis B[J].Aliment Pharmacol Ther,2004,20(11～12):1211.
4[4]Dan TM,Wagstaff A J.Emtricitabine/tenofovir disoproxil fumarate[J].Drugs,2004,64(18):2075.
5[7]Leung NW,Gish RG,Wang C,et al.A randomized,double-blind comparison of 3doses of emtricitabine in patients with chronic hepatitis B given 48 weeks of treatmen[J].Hepatology,2001,34:349A.
6[8]Gish RG,Letmg NW,Wright TL,et al.Dose range study of pharmacokinetics,safety,and preliminary antiviral activity of emtricitabine in adults with hepatitis B vires infection[J].Antimicrob Agents Chemother,2002,46(6):1734.
7[9]Nelson M,Schiavone M.Emtricitabine(FTC)for the treatmentof HIV infection[J].Int J Clin Pract,2004,58(5):504.
8[10]Saag MS,Cahn P,Raffi F,et al.Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients:a randomized trial[J].JAMA,2004,292(2):180～189.
